ProCE Banner Activity

POLARIX Trial of Polatuzumab Vedotin + R-CHP VS R-CHOP in Patients With Previously Untreated DLBCL

Slideset Download
Conference Coverage
In the phase III POLARIX trial, polatuzumab vedotin plus R-CHP significantly increased progression-free survival vs R-CHOP in patients with previously untreated intermediate- or high-risk DLBCL.

Released: December 17, 2021

Expiration: December 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation